Early treatment with antivirals ... disease course, prompting current clinical trials. The outbreak’s growth highlights urgent care challenges, with many deaths occurring before treatment and increased virus spread outside known transmission chains. ... Some doctors call it “walking Ebola” – symptoms of the rare Bundibugyo ... Early treatment with antivirals like remdesivir may improve survival due to the virus’ prolonged disease course, prompting current clinical trials. The outbreak’s growth highlights urgent care challenges, with many deaths occurring before treatment and increased virus spread outside known transmission chains. ... Some doctors call it “walking Ebola” – symptoms of the rare Bundibugyo strain appear to worsen slowly, leaving patients sick enough to spread the virus but not so unwell to stop them moving through their communities. Symptoms of the Bundibugyo strain seem to worsen slowly, so patients spread it as they're well enough to move about. Read more at straitstimes.com. Read more at straitstimes.com. If Bundibugyo gives doctors a longer opportunity to intervene before reaching that point, antiviral drugs may have a better chance of altering the course of the disease. The possibility has renewed interest in antiviral drugs such as Gilead Sciences’ remdesivir, which Levine’s lab found was more active against Bundibugyo than Zaire Ebola in petri-dish experiments. Researchers in July began testing remdesivir alongside Mapp Biopharmaceutical’s antibody therapy MBP134 in a World Health Organization-sponsored clinical trial in Congo, while a separate study is evaluating Gilead’s experimental oral antiviral obeldesivir in people recently exposed to the virus. Patients need aggressive fluids, treatment for shock, respiratory support and management of organ failure alongside antiviral drugs and antibodies. The Bundibugyo outbreak could similarly improve understanding of when antivirals work best, how to tailor supportive care and whether slowing the virus early changes the course of disease. If Levine’s hypothesis proves correct, the virus’ slower progression may give clinicians more time to deliver the intensive supportive care and antiviral medicines that have helped reduce Ebola mortality over the past decade.

Original title: “‘Walking Ebola’ helps explain why Congo’s outbreak is so hard to stop – and how to treat it | The Straits Times”

The strain of the virus that's responsible for the current outbreak has no specific treatments or preventive measures. Three new clinical trials could provide possible breakthroughs. There's no treatment designed for the Ebola strain ravaging DRC. But now there's hope The strain of the virus that's responsible for the current outbreak has no specific treatments or preventive measures. Three new clinical trials could provide possible breakthroughs. "We urgently need treatments that can help people affected by Bundibugyo virus disease," says Amanda Rojek, a physician scientist at the University of Oxford — that's a rarer species of Ebola than the much-researched Zaire strain behind many previous outbreaks. But because of that rarity, there are no specialized treatments to give patients. Nor are there drugs that might protect those exposed to the virus from getting sick. ... That reality is changing. Clinical trials are underway, or soon will be, to test new tools that health officials hope could help turn the tide against an outbreak that has already killed over 500 people and sickened more than 1,560 — and which some say could become the largest Ebola outbreak ever. BARDA is a U.S. government agency within the Department of Health and Human Services and the government has donated the doses necessary for the clinical trial, according to Vasee Moorthy, WHO's research and development lead for the outbreak. Each drug will be tested alone, and in combination, against the current standard of care — supportive therapy that aims to replace lost fluids and manage pain. A health worker takes a woman's temperature as part of Ebola screening efforts in Goma, Democratic Republic of Congo. As part of the effort to quash the outbreak, the first patients have been enrolled in a clinical trial to test two drugs against the Bundibugyo strain of the virus that is spreading there.

Original title: “There's no treatment designed for the Ebola strain ravaging DRC. But now there's hope : NPR”

Crisis preparedness and responseThe Management Board welcomed EMA’s support to African regulators in the context of the Ebola outbreak in the Democratic Republic of Congo and…

Original title: “EMA Management Board: highlights of June 2026 meeting”

EMA’s Emergency Task Force (ETF) is engaging with the African Medicines Agency (AMA) and its national regulatory authorities (NRAs), leveraging expertise from the WHO-AFRO…

Original title: “EMA, AMA and African regulatory authorities join forces on Ebola outbreak response”

The Centers for Disease Control and Prevention (CDC), as part of its continuing effort to reduce public burden and maximize the utility of government information, invites the general public and other federal agencies the opportunity to comment on a proposed information collection, as required by the Paperwork Reduction Act of 1995. This notice invites comment on a proposed information collection project titled 2026 Ebola Entry Screening, Monitoring, & Traveler Feedback. This data collection will

Original title: “Proposed Data Collection Submitted for Public Comment and Recommendations”

Riding a newfound surge of interest on infectious disease concerns, Moderna is linking up with a global vaccine foundation in hopes of developing a vaccine to slow the new surge in Ebola underway in the Congo and Uganda.

Original title: “Moderna partners with CEPI on Ebola vaccine efforts amid outbreak in Africa”

CDC has been responding and coordinating with the Ministry of Health of the Democratic Republic of the Congo (DRC) since a new outbreak of Ebola in North Kivu province was reported on July 30, 2018.

Original title: “CDC supporting response to new Ebola outbreak in North Kivu/Democratic Republic of the Congo”

The U.S. Centers for Disease control and Prevention (CDC) commends the dedicated efforts of the Democratic Republic of Congo (DRC) Ministry of Public Health and partners to end the ninth reported outbreak of Ebola in that country since 1976. This good news reinforces the importance of having efficient surveillance systems in place and strong leadership to stop outbreaks at their source and save lives.

Original title: “Statement from CDC Regarding Democratic Republic of Congo (DRC) Declaration on Official End of Ninth Ebola Outbreak”

SARS in 2003. Influenza in 2009. Ebola in 2014. Zika in 2015. In the fight against infectious diseases, no nation can stand alone. In today's interconnected world, a health threat anywhere is a threat everywhere: an outbreak in a remote village can spread to major cities on all six continents in less than 36 hours.

Original title: “Sustaining Global Health Security is Critical to Protecting America's National Security”

What was it like at ground zero of the worst outbreak of Ebola in history? This month, CDC's David J. Sencer Museum will be the first U.S. museum to offer an overview of the devastating viral outbreak that killed more than 11,000 people in West Africa.

Original title: “Life at Ground Zero: The Story of the West African Ebola Outbreak - Press Release”

CDC will host a media availability on June 28, 2017, for reporters who want to tour the new exhibition, EBOLA: People + Public Health + Political Will.

Original title: “CDC Hosts Media Availability for New Ebola Exhibition - Media Advisory”

Initial data from a Liberian public health program show about 9 percent (38) of 429 male Ebola survivors had fragments of Ebola virus in their semen.

Original title: “Traces of Ebola Virus Linger Longer than Expected in Semen - Press Release”

The Centers for Disease Control and Prevention (CDC) today will release a detailed account of the agency's work on the largest, longest outbreak response in the agency's history: the Ebola epidemic of 2014-2016. The series of articles, in a special supplement to CDC's Morbidity and Mortality Weekly Report (MMWR), comes on the second anniversary of the official activation of the agency's emergency response to Ebola.

Original title: “CDC Releases Detailed History of the 2014-2016 Ebola Response in MMWR - Press Release”

Finding points way to new approaches to Ebola treatment

Original title: “New study sheds light on how some survive Ebola - Press Release”

Building Response Capabilities in Liberia after Ebola

Original title: “Global Health Security - Liberia”

On Feb. 19, 2016, the Centers for Disease Control and Prevention (CDC) and the Department of Homeland Security (DHS) will remove Guinea from the list of nations affected by Ebola for which travelers are subject to enhanced U.S. visa and port-of-entry screening.

Original title: “Enhanced Entry Airport Screening and Routing for Ebola to End for Travelers from Guinea to the United States - Media Statement”

On Dec. 29, 2015, the Centers for Disease Control and Prevention (CDC) and the Department of Homeland Security (DHS) will modify enhanced Ebola port-of-entry screening for travelers from Guinea.

Original title: “Enhanced Entry Airport Screening for Ebola Modified for Travelers from Guinea to the United States”

On Dec. 22, 2015, the Centers for Disease Control and Prevention (CDC) and the Department of Homeland Security (DHS) will remove Sierra Leone from the list of nations affected by Ebola that are subject to enhanced visa and port-of-entry screening.

Original title: “Enhanced Entry Airport Screening for Ebola to End for Travelers from Sierra Leone to the United States - Media Statement”

On November 10, 2015, the Centers for Disease Control and Prevention (CDC) and the Department of Homeland Security (DHS) will modify enhanced Ebola port-of-entry screening for travelers from Sierra Leone.

Original title: “Modifications to Enhanced Entry Airport Screening for Travelers from Sierra Leone to the United States - Media Statement”